GENETHON Trademark
Trademark Overview
On Friday, June 6, 2003, a trademark application was filed for GENETHON with the United States Patent and Trademark Office. The USPTO has given the GENETHON trademark a serial number of 78259278. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, July 8, 2011. This trademark is owned by ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES. The GENETHON trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical and veterinary preparations for the treatment of diseases of genetic origin, in particular myopathies, fibrocystic diseases, immune deficiencies, in particular severe combined immuno-deficiency(SCID); medical, biotechnological and of gene technology-obtained preparations, namely, clinical medical reagents, diagnostic preparations for clinical or medical laboratory use, pharmaceutical or veterinary preparations for the treatment of diseases of genetic origin, microorganisms, cells, viruses, nucleotides, proteins, plasmids, DNA or RNA sequences, vectors consisting of DNA or RNA sequences, all for therapy and treatment of diseases of genetic origin
General Information
Serial Number | 78259278 |
Word Mark | GENETHON |
Filing Date | Friday, June 6, 2003 |
Status | 710 - CANCELLED - SECTION 8 |
Status Date | Friday, July 8, 2011 |
Registration Number | 2908354 |
Registration Date | Tuesday, December 7, 2004 |
Mark Drawing | 1000 - Typeset: Word(s) / letter(s) / number(s) |
Published for Opposition Date | Tuesday, September 14, 2004 |
Trademark Statements
Goods and Services | Pharmaceutical and veterinary preparations for the treatment of diseases of genetic origin, in particular myopathies, fibrocystic diseases, immune deficiencies, in particular severe combined immuno-deficiency(SCID); medical, biotechnological and of gene technology-obtained preparations, namely, clinical medical reagents, diagnostic preparations for clinical or medical laboratory use, pharmaceutical or veterinary preparations for the treatment of diseases of genetic origin, microorganisms, cells, viruses, nucleotides, proteins, plasmids, DNA or RNA sequences, vectors consisting of DNA or RNA sequences, all for therapy and treatment of diseases of genetic origin |
Classification Information
International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
US Class Codes | 006, 018, 044, 046, 051, 052 |
Class Status Code | 2 - Sec. 8 - Entire Registration |
Class Status Date | Friday, July 8, 2011 |
Primary Code | 005 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
Party Name | ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES |
Party Type | 30 - Original Registrant |
Legal Entity Type | 99 - Other |
Address | Paris Cedex 13 75651 FR |
Party Name | ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES |
Party Type | 20 - Owner at Publication |
Legal Entity Type | 99 - Other |
Address | Paris Cedex 13 75651 FR |
Party Name | ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES |
Party Type | 10 - Original Applicant |
Legal Entity Type | 99 - Other |
Address | Paris Cedex 13 75651 FR |
Trademark Events
Event Date | Event Description |
Friday, July 8, 2011 | CANCELLED SEC. 8 (6-YR) |
Sunday, March 16, 2008 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
Tuesday, December 7, 2004 | REGISTERED-PRINCIPAL REGISTER |
Tuesday, September 14, 2004 | PUBLISHED FOR OPPOSITION |
Wednesday, August 25, 2004 | NOTICE OF PUBLICATION |
Monday, June 28, 2004 | APPROVED FOR PUB - PRINCIPAL REGISTER |
Tuesday, May 4, 2004 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Tuesday, May 4, 2004 | PAPER RECEIVED |
Tuesday, November 4, 2003 | NON-FINAL ACTION MAILED |
Wednesday, October 22, 2003 | ASSIGNED TO EXAMINER |
Thursday, July 24, 2003 | CASE FILE IN TICRS |
Thursday, July 3, 2003 | PAPER RECEIVED |